Create an Account
  1. Home
  2. Meeting Reports
  3. The Imminent danger of Lp(a): Time to face to challenge

The Imminent danger of Lp(a): Time to face to challenge

Meeting report with video, highlights and slides of an EAS endorsed satellite meeting held prior to the 87th EAS congress in Maastricht, The Netherlands on the imminent danger of Lp(a) - videos will be added soon.

Episodes 1-9 of 9

  • Lpa and immune metabolismLpa and immune metabolism
    The Imminent danger of Lp(a): Time to face to challenge
    Lp(a) and immune metabolism
    • Jeffrey Kroon, PhD
      Jeffrey Kroon, PhD

      Jeffrey Kroon, PhD

  • Prevalence and relevance of elevated Lpa in familial hypercholesterolemiaPrevalence and relevance of elevated Lpa in familial hypercholesterolemia
    The Imminent danger of Lp(a): Time to face to challenge
    Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia
    • Prof. Børge Nordestgaard, MD
      Prof. Børge Nordestgaard, MD

      Prof. Børge Nordestgaard, MD

  • Lpa apheresis and CVD risk modulationLpa apheresis and CVD risk modulation
    The Imminent danger of Lp(a): Time to face to challenge
    Lp(a) apheresis and CVD risk modulation
    • Elisa Waldmann, MD
      Elisa Waldmann, MD

      Elisa Waldmann, MD

  • LDL vs Lpa cholesterol confoundingLDL vs Lpa cholesterol confounding
    The Imminent danger of Lp(a): Time to face to challenge
    LDL vs Lp(a) cholesterol: confounding
    • Calvin Yeang, MD, PhD
      Calvin Yeang, MD, PhD

      Calvin Yeang, MD, PhD

  • Phase II data on Lpa lowering followed by NHLBI recommendationPhase II data on Lpa lowering followed by NHLBI recommendation
    The Imminent danger of Lp(a): Time to face to challenge
    Phase II data on Lp(a) lowering, followed by NHLBI recommendation
    • Prof. Sam Tsimikas
      Prof. Sam Tsimikas

      Prof. Sam Tsimikas

  • Lpa and calcification in aortic stenosisLpa and calcification in aortic stenosis
    The Imminent danger of Lp(a): Time to face to challenge
    Lp(a) and calcification in aortic stenosis
    • Kang He Zheng, MD
      Kang He Zheng, MD

      Kang He Zheng, MD

  • Associations of Lpa with CV morbidity and mortalityAssociations of Lpa with CV morbidity and mortality
    The Imminent danger of Lp(a): Time to face to challenge
    Associations of Lp(a) with CV morbidity and mortality
    • Pia Kamstrup, MD, PhD
      Pia Kamstrup, MD, PhD

      Pia Kamstrup, MD, PhD

  • Entry of Lpa into the CV arenaEntry of Lpa into the CV arena
    The Imminent danger of Lp(a): Time to face to challenge
    Entry of Lp(a) into the CV arena
    • Prof. Florian Kronenberg, MD
      Prof. Florian Kronenberg, MD

      Prof. Florian Kronenberg, MD

  • Are we ready for primetime Lpa assay standardizationAre we ready for primetime Lpa assay standardization
    The Imminent danger of Lp(a): Time to face to challenge
    Are we ready for prime-time Lp(a) assay standardization?
    • Prof. Santica Marcovina
      Prof. Santica Marcovina

      Prof. Santica Marcovina

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free